ORI Capital

Summary

The company was established in Asia in Hong Kong. The leading representative office of defined VC is situated in the Wan Chai.

Opposing the other organizations, this ORI Capital works on 15 percentage points less the average amount of lead investments. The fund is constantly included in 2-6 deals per year. Considering the real fund results, this VC is 66 percentage points more often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The increased amount of exits for fund were in 2018. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity.

The current fund was established by Simone Song. We also calculated 2 valuable employees in our database.

Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Orchard Therapeutics, Surefire Medical, Enable Injections The fund has specific favorite in a number of founders of portfolio startups. When startup sums 3 or 5+ of the founder, the probability for it to get the investment is little. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Therapeutics, Medical Device.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the ORI Capital, startups are often financed by Partisan Management Group, High Country Venture, Wellcome Trust. The meaningful sponsors for the fund in investment in the same round are Partisan Management Group, Temasek Holdings, Ohio Innovation Fund. In the next rounds fund is usually obtained by Venrock, Temasek Holdings, Sphera Global Healthcare Fund.